This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kerr, D. J. Articles by Soukop, M. Search for Related Content PubMed PubMed Citation Articles by Kerr, D. J. Articles by Soukop, M.

Phase I and Pharmacokinetic Study of LM985 (Flavone Acetic Acid Ester)¹

Department of Medical Oncology [D. J. K., S. B. K., J. G., J. C., M. H., A. S.] and Institute of Physiology [J. C. M.], University of Glasgow, Department of Pharmacy, University of Strathclyde [W. R. V.], and Department of Medical Oncology, Royal Infirmary [D. C., G. F., M. S.], Glasgow, Scotland

We have conducted a Phase I and initial clinical pharmacological evaluation of LM985, the first of a series of compounds based on the flavone ring structure to be considered for clinical trial in malignant disease. The drug was administered i.v. to 26 patients with advanced cancer on an every-21-day schedule. Patients were treated at 14 dosage levels ranging from 10 to 1500 mg/m². Dose limiting toxicity was identified as acute reversible hypotension occurring during drug infusion; no leukopenia, alopecia, hepatic toxicity, or renal toxicity was observed, but at the higher dose range, mild sedation was apparent. Twenty patients had measurable disease and were evaluable for response. One patient with colorectal carcinoma had stable disease after three courses of LM985; however, no other responses were seen. Pharmacokinetic and in vitro drug degradation studies imply that the ester LM985 is hydrolyzed to LM975 (flavone acetic acid) rapidly in vivo. LM975 is active in a variety of animal tumor models, but it does not have the cardiovascular side effects seen with LM985 (hypotension and bradycardia) in pithed or anesthetized rats. We would recommend that LM975 be considered for clinical trial, because it seems likely that substantially higher doses of LM975 than of LM985 can be given without dose limiting cardiovascular toxicity.

¹ Perfomed under the auspices of the Cancer Research Campaign.

² To whom requests for reprints should be addressed, at Department of Medical Oncology, University of Glasgow, 1 Horselethill Road, Glasgow G12 9LX, Scotland.

Received 8/26/85. Revised 12/30/85. Revised 3/ 5/86. Accepted 3/ 7/86.